Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

@article{Lencioni2016SorafenibOP,
  title={Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.},
  author={Riccardo A Lencioni and Josep M Llovet and Guo-hong Han and Won Young Tak and Jia-mei Yang and Alfredo Guglielmi and Seung Woon Paik and Mar{\'i}a Elisa Reig and Do Young Kim and G Y Chau and Angelo Luca and Luis Ruiz del {\'A}rbol and Marie-Aude Leberre and Woody Niu and Kate Nicholson and Gerold Meinhardt and Jordi Bruix},
  journal={Journal of hepatology},
  year={2016},
  volume={64 5},
  pages={1090-1098}
}
BACKGROUND & AIMS Transarterial chemoembolization with doxorubicin-eluting beads (DC Bead®; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B hepatocellular carcinoma (HCC). The multikinase inhibitor sorafenib enhances overall survival (OS) and time-to-tumor progression (TTP) in patients with advanced HCC. This exploratory phase II trial tested the efficacy and safety of DEB-TACE plus sorafenib in patients with intermediate stage HCC. METHODS Patients with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 34 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

References

Publications referenced by this paper.

Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC

  • R. Lencioni, J. M. Llovet, +16 authors J. Bruix
  • 2015

Similar Papers

Loading similar papers…